Diabetes
Refine Search
Pharmaceutical
Danish diabetes care giant Novo Nordisk saw its shares rise 3.7% to 673.90 kroner today, on positive news announced to the stock exchange late on Tuesday. 11 October 2023
Pharmaceutical
Lifera, a biopharmaceutical company wholly-owned by the Saudi Arabian Public Investment Fund (PIF), says it has successfully completed its acquisition of a 70% stake in SaudiBio. 11 October 2023
Biotechnology
USA-based immunotherapy specialist SAB Biotherapeutics has raised $130 million in a private share placement. 10 October 2023
Generics
India’s Biocon has signed a partnership agreement with Canadian specialty pharma company Juno Pharmaceuticals, for the commercialization of its vertically integrated, complex formulation, liraglutide, a drug-device combination for the treatment and management of type 2 diabetes and obesity. 9 October 2023
Pharmaceutical
Positive results from the T2NOW Phase III trial have demonstrated significant reduction in A1C, a marker of average blood sugar, for patients treated with Forxiga/Farxiga (dapagliflozin) compared to those receiving placebo. 4 October 2023
Pharmaceutical
US pharma major Eli Lilly today revealed that Mike Mason, executive vice president and president of Lilly Diabetes and Obesity, will retire at the end of 2023 after 34 years with the company. 4 October 2023
Pharmaceutical
Danish diabetes care giant Novo Nordisk’s obesity medication Wegovy (semaglutide) will soon be accessible through the National Health Service (NHS) in England, albeit with limited supply. 4 October 2023
Biotechnology
US clinical-stage biopharma firm Structure Therapeutics’ leapt almost 66% to $62.06 in pre-market activity, after it delivered better-than-expected efficacy and tolerability for its oral GLP-1 GSBR-1290. 29 September 2023
Biotechnology
China’s tension between the US-led West, its down-sliding economy and the increasingly wayward policy making all added to the factors that made investors seek different ways to grow their businesses in the country, said speakers at ChinaBio partnering forum held on September 20 in Shanghai. 25 September 2023
Biosimilars
Chicago, USA-based Meitheal Pharmaceuticals has announced an exclusive licensing agreement with Tonghua Dongbao Pharmaceutical to commercialize three insulin biosimilars in the USA. 22 September 2023
Biotechnology
It may feel like groundhog day for the beleaguered backers of a novel drug-device product developed by biotech unicorn Intarcia Therapeutics. 22 September 2023
Pharmaceutical
Research from a medical testing company, London Medical Laboratory, finds that there is a “critical medication shortage” facing many diabetics in the UK. 21 September 2023
Pharmaceutical
US pharma major Eli Lilly has revealed it suing spas, wellness centers and compounding pharmacies selling unapproved and compounded versions of its type 2 diabetes drug Mounjaro (tirzepatide). 20 September 2023
Pharmaceutical
Around 180,000 people in England and Wales with difficult to manage type 2 diabetes could benefit from a new treatment option recommended by the National Institute for Health and Care Excellence (NICE. 11 September 2023
Pharmaceutical
Boston, USA-based Glyscend Therapeutics, which is developing a revolutionary approach to treating type 2 diabetes, has appointment of Sapan Shah as chief executive (CEO). 8 September 2023
Pharmaceutical
Swiss drugmaker Novartis has launched legal action against the US government, after administrators revealed the first drugs to be subject to pricing regulations mandated by the Inflation Reduction Act (IRA). 7 September 2023
Pharmaceutical
Cardiometabolic med Jardiance (empagliflozin), a blockbuster product developed by Boehringer Ingelheim and Eli Lilly, has picked up a new approval in the UK. 7 September 2023
Generics
Russian drugmaker Geropharm once again failed to challenge the patent for Toujeo (long-acting insulin glargine) produced by the French pharma major Sanofi, reports The Pharma Letter’s local correspondent. 5 September 2023
Pharmaceutical
In a bid to consolidate its lead in the weight management therapy sector, diabetes care giant Novo Nordisk has now bought a fellow Denmark based company and its obesity program. 30 August 2023
Pharmaceutical
Today, the US Centers for Medicare & Medicaid Services (CMS) has for the first time selected 10 drugs for negotiation. Seniors paid $3.4 billion in out-of-pocket costs for these drugs in 2022, the CMS stated. 29 August 2023
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca beat analyst expectations with its third-quarter 2024 revenue and earnings figures. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze